# Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis

> **NCT00931411** · NA · TERMINATED · sponsor: **Cosmetique Active International** · enrollment: 73 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **OTHER:** Formulation 609580 20
- **OTHER:** Formulation 609209 (Lipikar Baume)

## Key facts

- **NCT ID:** NCT00931411
- **Lead sponsor:** Cosmetique Active International
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-07
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** Patients would improve naturally due to weather conditions
- **Last updated:** 2011-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00931411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00931411, "Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00931411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*